CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The ISOS project develops a biomedical product that uses genetically engineered probiotic bacteria to produce therapeutic compounds on demand. This innovative approach aims to treat chronic diseases by delivering personalized treatments through an implantable bioreactor, specifically targeting age-related macular degen…
In ISOS we propose to develop the first biomedical product for the in-situ fabrication and auto-renewed delivery of therapeutic compounds employing complex ecosystems of probiotic genetically engineered bacteria (GEB) integrated in a biomaterial-based bioreactor. ISOS is designed to treat chronic diseases requiring lengthy treatments.
The encapsulated GEB populations produce the therapeutic molecules ""on demand"", stimulated by the signals of the pathological environment within the patient, i.e…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Spain, Madrid
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Germany, Leipzig
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Italy, ROMA
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
